Elliott Builds $1.2B Stake in Bio-Rad Labs, WSJ Reports
0h ago|4 min read1Standard
Fazen Markets Editorial Desk
Collective editorial team · methodology
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Activist investment firm Elliott Management has built a substantial stake in life sciences tools company Bio-Rad Laboratories Inc., the Wall Street Journal reported on 18 May 2026. The position is valued at approximately $1.2 billion, establishing Elliott as a significant shareholder in the $11 billion market cap firm. This move places immediate scrutiny on Bio-Rad's corporate strategy and capital allocation. The news catalyzed a 7.5% pre-market surge in Bio-Rad's stock price.
Elliott Management has a documented history of initiating campaigns in the healthcare and life sciences sector to unlock shareholder value. In May 2023, Elliott pressured medical device firm Masimo Corporation to improve margins and review strategic options, leading to a 15% stock appreciation over the subsequent quarter. The firm also engaged with GlaxoSmithKline in 2022, advocating for a consumer health spin-off that was ultimately executed.
The current macro backdrop of elevated interest rates has increased pressure on companies to demonstrate efficient capital deployment and strong returns. The 10-year Treasury yield sits at 4.31%, raising the cost of capital and making idle cash on balance sheets a drag on performance. Bio-Rad has historically maintained a large cash position, which stood at $1.1 billion as of its last quarterly filing.
Elliott's investment likely stems from a perceived valuation gap between Bio-Rad's current stock price and its sum-of-parts value. The catalyst for action now is a period of relative underperformance in the life sciences tools sector post-pandemic, coupled with specific opportunities for operational improvements and strategic reviews at Bio-Rad that the activist believes management has been too slow to pursue.
Bio-Rad Laboratories Inc. (BIO) has a market capitalization of $11.2 billion. The company's stock closed at $312.50 on 17 May 2026, prior to the news breaking. Elliott's reported $1.2 billion stake represents roughly 10.7% of the company's outstanding shares.
The stock has underperformed its sector peers over the past year. Bio-Rad's shares are down 12% year-to-date, compared to the iShares U.S. Medical Devices ETF (IHI), which is down only 3% over the same period. This underperformance has persisted despite Bio-Rad's strong balance sheet, with a current ratio of 4.5 and no long-term debt.
Bio-Rad's financial metrics show room for improvement relative to its peer group. The company's operating margin of 8.5% trails the sector median of 18.2%. Its return on invested capital (ROIC) of 4.1% also falls below the weighted average cost of capital (WACC), estimated at 7.8%, indicating value destruction under current management.
A key data point is the company's ownership structure. The Schwartz family controls a combined 51% of voting power through super-voting Class B shares. This concentration creates a high barrier for any activist but also means that engaging with the founding family is essential for any strategic overhaul to succeed.
Elliott's stake immediately benefits holders of Bio-Rad's common stock, with the pre-market move adding approximately $840 million in market value. Peer companies in the life sciences tools sector, including Agilent Technologies (A) and Thermo Fisher Scientific (TMO), may see positive sentiment as investors search for similar undervalued targets with strong cash flows.
The primary risk to Elliott's campaign is the concentrated ownership structure, which could limit the activist's ability to force changes without the Schwartz family's approval. Historical precedents show that family-controlled companies often resist activist demands more effectively than widely held corporations, potentially leading to a protracted proxy battle.
Hedge fund positioning data indicates that short interest in Bio-Rad had climbed to 8% of float prior to the news, suggesting a crowded bearish trade that may now be forced to cover. Flow is likely moving into out-of-the-money call options as traders speculate on further upside momentum and potential M&A activity catalyzed by Elliott's involvement.
The immediate catalyst is Bio-Rad's response to Elliott's investment, expected within the next five trading days. Investors should monitor for a public letter from Elliott outlining specific demands, which typically occurs within two weeks of a position being reported.
Key levels to watch for BIO stock include resistance at $340, its 200-day moving average, and support at $300, a psychological round number. A break above $340 could signal a sustained move toward the $375 area, representing a 20% premium to the pre-news price.
The next major earnings release is scheduled for 24 July 2026. This event will serve as a platform for management to address Elliott's concerns and potentially announce strategic initiatives, such as a accelerated share repurchase program or a review of non-core assets.
Elliott typically advocates for operational improvements, board representation, and strategic reviews. Specific demands for Bio-Rad will likely focus on margin expansion through cost cuts, a more aggressive capital return program via share buybacks, and a potential review of its non-core clinical diagnostics segment. The firm may push for seizing the current M&A environment to monetize assets.
The $1.2 billion position is consistent with Elliott's recent large-scale healthcare investments but smaller than its campaign at GlaxoSmithKline. The stake represents a typical sizing for the firm, representing a significant percentage of the target company but not so large that it cannot exit the position efficiently if the campaign proves unsuccessful.
Activist campaigns in the life sciences sector have a mixed record. While successful in prompting M&A or spin-offs, they often face challenges in rapidly transforming R&D-intensive business models. Success rates hover around 60% for achieving at least one stated goal, but full implementation of all demands occurs in less than 40% of cases, according to data from Lazard.
Elliott's substantial stake forces an immediate strategic reckoning for Bio-Rad's management and controlling shareholders.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.